# Sorbent Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sorbent-therapeutics

- Industry: Biopolymers
- Headquarters: Sunnyvale, US
- Website: www.sorbent.com
- Total disclosed funding: $111M
- Latest round: Series D (May 15, 2014)
- Investors on record: 8

## About

Sorbent Therapeutics develops advanced therapeutic solutions to address unmet medical needs, particularly in the fields of gastrointestinal health and drug delivery systems.Founded in 2005, Sorbent Therapeutics is based in Sunnyvale, US, focusing on innovative therapeutic products. The company raised USD 6.5 mn in its Series D funding round on May 15, 2014, with investments from ARCH Venture Partners, AgeChem, Novartis Venture Fund, and others. Sorbent has completed 8 deals to date.Sorbent specializes in a range of therapeutic solutions aimed at gastrointestinal health, including drug delivery systems designed to enhance patient outcomes. Their innovative products target specific medical conditions, addressing critical healthcare requirements through advanced technology and research.Sorbent generates revenue from sales of its therapeutic products through direct-to-consumer channels and partnerships with healthcare providers. The distribution strategy encompasses various healthcare networks, ensuring accessibility of their specialized products to patients in need.Sorbent Therapeutics aims to expand its product line with new therapeutic offerings set to launch in the near future, utilizing insights from extensive research and development. The company is also targeting expansion into international markets, specifically aiming to enter Europe and Asia by 2025. The recent funding of USD 6.5 mn will support these initiatives, enhancing product development and marketing efforts.

## Funding rounds

- Series D, May 15, 2014, $6.5M — ARCH Venture Partners, Sofinnova Investments, Novartis Venture Fund, Presidio Partners, AgeChem
- Series C, Mar 31, 2013, $2.5M — ARCH Venture Partners
- Series C, Aug 7, 2012, $18M — ARCH Venture Partners, Sofinnova Investments, Novartis Venture Fund, Presidio Partners
- Series B, Jun 30, 2011, $36M — ARCH Venture Partners, Sofinnova Investments, Novartis Venture Fund, Presidio Partners, GeneChem
- Series B, Sep 10, 2010, $5M — ARCH Venture Partners, Sofinnova Investments, Presidio Partners, GeneChem, Dow Venture Capital
- Series B, Jun 30, 2010, $17M — ARCH Venture Partners, Sofinnova Investments, Presidio Partners
- Series A, Jan 25, 2007, $7M — ARCH Venture Partners, Dow Venture Capital
- Series A, Feb 7, 2006, $19M — ARCH Venture Partners, Sofinnova Investments, Presidio Partners, The Dow Chemical Company

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B, Series C, Series D
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A, Series B, Series C, Series D
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series A, Series B, Series C, Series D
- The Dow Chemical Company — Series A
- Dow Venture Capital (https://capitalatlas.ai/funds/dow-venture-capital) — Series A, Series B
- GeneChem (https://capitalatlas.ai/funds/genechem) — Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B, Series C, Series D
- AgeChem (https://capitalatlas.ai/funds/agechem) — Series D